Studies on Experimental Iodine Allergy: 1. Antigen Recognition of Guinea Pig Anti-Iodine Antibody

Total Page:16

File Type:pdf, Size:1020Kb

Studies on Experimental Iodine Allergy: 1. Antigen Recognition of Guinea Pig Anti-Iodine Antibody The Journal of Toxicological Sciences, 131 Vol.29, No.2, 131-136, 2004 STUDIES ON EXPERIMENTAL IODINE ALLERGY: 1. ANTIGEN RECOGNITION OF GUINEA PIG ANTI-IODINE ANTIBODY Hiroshi SHIONOYA1 Yoshiki SUGIHARA2, Kazuo OKANO3, Fumio SAGAMI1, Takashi MIKAMI1 and Kouichi KATAYAMA3 1Department of Drug Safety Research, Eisai Kawashima Research Laboratories, Eisai Co., Ltd., 1 Takehaya-cho, Kawashima-cho, Hashima-gun, Gifu 501-0061, Japan 2Department of Drug Safety Research, Eisai Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3 Tohkodai, Tsukuba-shi, Ibaraki 300-2635, Japan 3Exploratory Division, Eisai Tsukuba Research Laboratories, Eisai Co., Ltd., 5-1-3 Tohkodai, Tsukuba-shi, Ibaraki 300-2635, Japan (Received September 3, 2003; Accepted February 18, 2004) ABSTRACT — It has generally been thought that iodine allergy is cross-sensitive to various iodine-con- taining chemicals. However, this concept seems to deviate from the immunological principle that immune recognition is specific. To solve this contradiction, we hypothesize that iodine allergy is an immunological reaction to iodi- nated autologous proteins produced in vivo by iodination reaction from various iodine-containing chemi- cals. Antisera to iodine were obtained from guinea pigs immunized subcutaneously with iodine-potassium iodide solution emulsified in complete Freund’s adjuvant (CFA). The specificity of guinea pig anti-iodine antiserum was determined by enzyme-linked immunosorbent assay (ELISA) inhibition experiments using microplates coated with iodinated guinea pig serum albumin (I-GSA). Antibody activities were inhibited by I-GSA, diiodo-L-tyrosine, and thyroxine, but not by potassium iodide, monoiodo-L-tyrosine, 3,5,3’-tri- iodothyronine, monoiodo-L-histidine, or diiodo-L-histidine, or by ionic or non-ionic iodinated contrast media. The results that antigen recognition of anti-iodine antibody is specific to iodinated protein support our hypothesis. While protein iodination usually takes place both at histidine residues as well as at tyrosine residues, only iodinated tyrosine acted as an antigenic determinant and no antibody activities to iodinated histidine were detected in our experimental iodine allergy model. KEY WORDS: Iodine allergy, Anti-iodine antibody, Iodotyrosine, Guinea pig, Iodocontrast media INTRODUCTION In order to solve this contradiction, we hypothe- size that iodine allergy is an immunological reaction to The term iodine allergy has been defined gener- iodinated autologous proteins produced in vivo by iodi- ally as “an allergic reaction induced by the use of nation reaction from various iodine-containing chemi- iodine-containing drugs” such as inorganic iodine cals. Iodination of protein by iodine occurs readily, preparations used as a skin disinfectant or various even at physiological pH (Hughes and Straessle, 1950). organic iodine-containing drugs. Accordingly it has Iodine molecules are substituted for hydrogen atoms on generally been thought that iodine allergy is cross-sen- the phenol rings of tyrosyl residues and on the imida- sitive to various iodine-containing chemicals. However, zole rings of histidyl residues (Covelli and Wolff, this concept seems to deviate from the immunological 1966). Experimental studies on immunogenicity of principle that immune recognition is specific. iodine (Ishikawa, 1953) and iodinated homologous Correspondence: Yoshiki SUGIHARA Vo l . 2 9 N o . 2 132 H. SHIONOYA et al. serum proteins (Jacobs, 1932) have been reported. Spe- was injected subcutaneously at a total volume of 0.5 ml cific precipitin reaction inhibition by diiodotyrosine in (0.125 ml per site at four separate positions or 0.25 ml a system consisting of iodinated sera and their antisera per site at two separate positions) into the back of five was first reported in 1930 by Wormall (Wormall, guinea pigs at intervals of 2 weeks. The dose of iodine 1930). Jacobs has confirmed these results and also was therefore 1 mg per animal for each immunization. reported that potassium iodide did not inhibit the pre- After five-time immunizations, animals were bled and cipitin reaction (Jacobs, 1932). However, there has the sera separated were pooled and preserved at −20°C. been no report on the specificity of antigen recognition An antibody titer of pooled sera by passive cutaneous of anti-iodine antibody, especially in relation to cross- anaphylaxis (PCA) test was 4000 using an iodinated sensitization of iodine allergy. Accordingly, it is impor- guinea pig serum albumin (I-GSA 7.2 as mentioned in tant to reveal the specificity of anti-iodine antibody for the next paragraph) as an eliciting antigen. better understanding of the mechanism of iodine allergy. Therefore, we performed this study to observe Preparation of iodinated proteins the antigen recognition of anti-iodine antibody using Iodinated guinea pig serum albumin for ELISA an experimental iodine allergy model. inhibition experiment and PCA test was prepared at pH 7.2, (as for in vivo iodination of protein) as follows. MATERIALS AND METHODS Thirty µl of 0.5 M iodine was added to 1 ml of a 10 mg/ ml solution of GSA in phosphate buffer saline (PBS, Animals and reagents pH 7.2) and incubated at 37°Covernight;pHwas Female Hartley strain guinea pigs, at the age of 4 maintained at 7.2 by adding 1 M sodium carbonate. weeks, were purchased from Nippon SLC The residual iodine in the reactants was reduced by (Hamamatsu, Japan). They were acclimated for 2 adding 0.1 M sodium thiosulfate and the reactants were weeks before use. Iodine (I2) and potassium iodide then dialyzed against PBS. The preparation was (KI) were obtained from Katayama Chemical Indus- referred to as I-GSA 7.2. Because the maximum iodi- tries (Osaka, Japan). L-Tyrosine disodium salt (Tyr), 3- nation of protein takes place at an alkaline pH (Hughes iodo-L-tyrosine (MIT), L-histidine (His), 3,5,3’-tri- and Straessle, 1950), iodinated GSA used in ELISAs iodothyronine (T3), thyroxine (T4), guinea pig serum was prepared as follows. An aliquot of 50 µl of 0.5 M albumin (GSA), were purchased from Sigma (St Louis, iodine was added to 1 ml of 5 mg/ml solution of GSA MO, USA). 3,5-Diiodo-L-tyrosine (DIT) was pur- in 0.1 M borate buffer, pH 9.5, and incubated at 37°C chased from Nacalai Chemicals (Kyoto, Japan). 4- overnight. The residual iodine in the reactant was Monoiodo-L-histidine (MIH) and 2,4-diiodo-L-histi- reduced and dialyzed against 0.1 M borate buffer at pH dine (DIH) were synthesized in our laboratories. The 9.5. The preparation was referred to as I-GSA 9.5. λ 1% ionic radiocontrast media and non-ionic contrast media max andE 1CM of I-GSA 9.5 were 311 nm and 16.9, used were amidotrizoic acid (Urografin; Schering respectively. The shift of λ max from 280 of GSA to Japan, Osaka, Japan), iodamide (Conraxin; Bracco, 311 nm of I-GSA 9.5 compares favorably with that of Milan, Italy), ioxaglic acid (Hexablix; Tanabe Pharm., tyrosine from 293 nm to 311 nm by di-iodination Osaka, Japan), iopamidol (Iopamiron; Schering (Hughes and Straessle, 1950). Under the iodination Japan), iohexol (Omnipaque; Daiichi Pharm., Tokyo, conditions employed, all the tyrosine residues and Japan) and iomeprol (Iomeron; Eisai, Tokyo, Japan). almost all the histidine residues were considered to be Protein assays were performed using BCA protein changed to di-iodinated ones when human serum albu- assay reagent (Pierce, Rockford, IL, USA). Bovine min (containing 18 tyrosine and 16 histidine residues serum albumin (BSA) standard solution attached to the per mol) was used (Hughes and Straessle, 1950). For assay reagent was used as a standard. the purpose of confirming potency of I-GSA 9.5 to detect antibodies which were produced by immuniza- Immunization of guinea pigs tion of guinea pigs with iodinated protein, I-GSA 7.2, Animal handling for all procedures such as injec- ELISA inhibition experiments were performed using tions and bleedings was performed under pentobarbital iodinated histidine and tyrosine as an inhibiting hap- sodium anesthesia. Iodine solution (4 mg/ml; I2/KI = ten. The results are shown in Fig. 1, indicating that I- 1.269: 2.50, W/W) was emulsified with an equal vol- GSA 9.5 detected antibodies to either iodinated histi- ume of CFA (Difco, Detroit, MI, USA). The emulsion dine or tyrosine. Vo l . 2 9 N o . 2 133 Experimental iodine allergy: 1. Specificity of anti-iodine antibody. ELISA inhibition experiments for anti-iodine anti- The absorbance at 490 nm was measured with a model body 3550 microplate reader (BioRad, Richmond, CA, I-GSA 9.5 was coated onto microtiter plates USA). Each sample was assayed in triplicate. (Coster, Cambridge, MA, USA). After blocking unoc- cupied plastic sites with bovine serum albumin (BSA, RESULTS Sigma), anti-iodine antisera previously incubated at 4°C overnight with test compounds for ELISA inhibi- The effects of inorganic iodine (KI) and iodinated tion were added to each well, followed by incubation at organic derivatives on antigen-antibody reactions were 37°C for 1 hr. After washing the plates, they were incu- studied in ELISA inhibition experiments using antisera bated with peroxidase-conjugated goat anti-guinea pig obtained from guinea pigs immunized with iodine and IgG (heavy and light chain-specific, Cooper Biochem- microplates coated with I-GSA 9.5. ical, Malvern, PA, USA) and washed. Peroxidase sub- A fourfold serial dilution of the antisera was per- strate solution containing o-phenylenediamine (Sigma) formed with PBS containing 1% BSA, 0.05% Tween and hydrogen peroxide was then added to each well. 20, and 3% sodium chloride as a diluent. To 0.1 ml of The plates were kept for 30 min at room temperature, the diluted sera, 0.1 ml of test material solution for and 3N hydrochloric acid was then added to each well. ELISA inhibitory activity was added and incubated at 4°C overnight. Antibody activities were then assayed on the microplates coated with I-GSA 9.5.
Recommended publications
  • Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation
    PHARMACY REENGINEERING (PRE) Version 0.5 Pre-Release Implementation Guide PSS*1*129 & PSS*1*147 February 2010 Department of Veterans Affairs Office of Enterprise Development Revision History Date Revised Patch Description Pages Number 02/2010 All PSS*1*147 Added Revision History page. Updated patch references to include PSS*1*147. Described files, fields, options and routines added/modified as part of this patch. Added Chapter 5, Additive Frequency for IV Additives, to describe the steps needed to ensure correct data is in the new IV Additive REDACTED 01/2009 All PSS*1*129 Original version REDACTED February 2010 Pharmacy Reengineering (PRE) V. 0.5 Pre-Release i Implementation Guide PSS*1*129 & PSS*1*147 Revision History (This page included for two-sided copying.) ii Pharmacy Reengineering (PRE) V. 0.5 Pre-Release February 2010 Implementation Guide PSS*1*129 & PSS*1*147 Table of Contents Introduction ................................................................................................................................. 1 Purpose ....................................................................................................................................1 Project Description ....................................................................................................................1 Scope ........................................................................................................................................3 Menu Changes ..........................................................................................................................4
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacologyonline 2: 727-753 (2010) Ewsletter Bradu and Rossini
    Pharmacologyonline 2: 727-753 (2010) ewsletter Bradu and Rossini COTRAST AGETS - IODIATED PRODUCTS. SECOD WHO-ITA / ITA-OMS 2010 COTRIBUTIO O AGGREGATE WHO SYSTEM-ORGA CLASS DISORDERS AD/OR CLUSTERIG BASED O REPORTED ADVERSE REACTIOS/EVETS Dan Bradu and Luigi Rossini* Servizio Nazionale Collaborativo WHO-ITA / ITA-OMS, Università Politecnica delle Marche e Progetto di Farmacotossicovigilanza, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Regione Marche, Italia Summary From the 2010 total basic adverse reactions and events collected as ADRs preferred names in the WHO-Uppsala Drug Monitoring Programme, subdivided in its first two twenty years periods as for the first seven iodinated products diagnostic contrast agents amidotrizoate, iodamide, iotalamate, iodoxamate, ioxaglate, iohexsol and iopamidol, their 30 WHO-system organ class disorders (SOCDs) aggregates had been compared. Their common maximum 97% levels identified six SOCDs only, apt to evaluate the most frequent single ADRs for each class, and their percentual normalization profiles for each product. The WILKS's chi square statistics for the related contingency tables, and Gabriel’s STP procedure applied to the extracted double data sets then produced profile binary clustering, as well as Euclidean confirmatory plots. They finally showed similar objectively evaluated autoclassificative trends of these products, which do not completely correspond to their actual ATC V08A A, B and C subdivision: while amidotrizoate and iotalamate, and respectively iohesol and iopamidol are confirmed to belong to the A and B subgroups, ioxaglate behaves fluctuating within A, B and C, but iodamide looks surprizingly, constantly positioned together with iodoxamate as binary/ternary C associated. In view of the recent work of Campillos et al (Science, 2008) which throws light on the subject, the above discrepancies do not appear anymore unexpected or alarming.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Informe Tecnico Ufurm-Dfau-Digemid/Minsa
    “Año del Buen Servicio al Ciudadano” ” INFORME TECNICO UFURM-DFAU-DIGEMID/MINSA Proceso: Proceso de revisión y actualización de Petitorio Nacional Único de Medicamentos Esenciales (PNUME) Solicitante: Equipo Técnico para el proceso de revisión y actualización del PNUME I. DATOS DE LA SOLICITUD Medicamento solicitado: Ioversol 320 mg Iodo/mL inyectable Indicación específica: Arteriografía cerebral, periférica, visceral y renal utilizando las técnicas convencionales o la técnica por sustracción digital intra-arterial e intravenosa Institución que lo EsSalud solicita: Número de casos anuales: Motivo de la solicitud Criterios fundamentales 1. Medicamento de eficacia y seguridad demostrada para cubrir vacío importante. 2. Igual eficacia y mayor seguridad e igual o menor costo de tratamiento a las alternativas del PNUME Criterios complementarios No reporta Medicamento solicitado: Ácido ioxaglico (como sal de sodio y meglumina) 320 mg Iodo/mL inyectable Indicación específica: Arteriografia cerebral, periferica, visceral y renal en pacientes con alto riesgo cardiovascular; flebografía y urografía intravenosa; TAC craneal y de cuerpo completo Institución que lo EsSalud solicita: Número de casos anuales: Motivo de la solicitud Criterios fundamentales 1. Medicamento de eficacia y seguridad demostrada para cubrir vació importante. 2. Igual eficacia y mayor seguridad e igual o menor costo de tratamiento a las alternativas del PNUME Criterios complementarios No reporta Medicamento solicitado: Iobitridol 300 mg Iodo/mL inyectable Indicación específica: Indicado en la realización de tomografía (TAC) e intervencionismo; estudios urográficos convencionales; la dosis debe adaptarse al examen y a los territorios que se pretende opacificar, asi como al peso y a la función renal del sujeto, especialmente en el niño Institución que lo Hospital Hipólito Unanue solicita: Número de casos anuales: Motivo de la solicitud Criterios fundamentales “Año del Buen Servicio al Ciudadano” ” 1.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Pharmacy Data Management Drug Exception List
    Pharmacy Data Management Drug Exception List Patch PSS*1*127 updated the following drugs with the listed NCPDP Multiplier and NCPDP Dispense Unit. These two fields were added as part of this patch to the DRUG file (#50). Please refer to the Release notes for ePharmacy/ECME Enhancements for Pharmacy Release Notes (BPS_1_5_EPHARMACY_RN_0907.PDF) on the VistA Documentation Library (VDL). The IEN column reflects the IEN for the VA PRODUCT file (#50.68). The ePharmacy Change Control Board provided the following list of drugs with the specified NCPDP Multiplier and NCPDP Dispense Unit values. This listing was used to update the DRUG file (#50) with a post install routine in the PSS*1*127 patch. NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 2 ATROPINE SO4 0.4MG/ML INJ 1.00 ML 3 ATROPINE SO4 1% OINT,OPH 3.50 GM 6 ATROPINE SO4 1% SOLN,OPH 1.00 ML 7 ATROPINE SO4 0.5% OINT,OPH 3.50 GM 8 ATROPINE SO4 0.5% SOLN,OPH 1.00 ML 9 ATROPINE SO4 3% SOLN,OPH 1.00 ML 10 ATROPINE SO4 2% SOLN,OPH 1.00 ML 11 ATROPINE SO4 0.1MG/ML INJ 1.00 ML 12 ATROPINE SO4 0.05MG/ML INJ 1.00 ML 13 ATROPINE SO4 0.4MG/0.5ML INJ 1.00 ML 14 ATROPINE SO4 0.5MG/ML INJ 1.00 ML 15 ATROPINE SO4 1MG/ML INJ 1.00 ML 16 ATROPINE SO4 2MG/ML INJ 1.00 ML 18 ATROPINE SO4 2MG/0.7ML INJ 0.70 ML 21 ATROPINE SO4 0.3MG/ML INJ 1.00 ML 22 ATROPINE SO4 0.8MG/ML INJ 1.00 ML 23 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,5ML 5.00 ML 24 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,10ML 10.00 ML 25 ATROPINE SO4 1MG/ML INJ,AMP,1ML 1.00 ML 26 ATROPINE SO4 0.2MG/0.5ML INJ,AMP,0.5ML 0.50 ML 30 CODEINE PO4 30MG/ML
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Gadoxetic Acid (Rinn) Preparations Acide Gadoxétique; Ácido Gadoxético; Acidum Gadoxeticum; Pharmacopoeias
    Gadoteric Acid/Iodamide 1481 Preparations cholangiopancreatography, and hysterosalpingography. It is also used for contrast enhancement in computed tomography. USP 31: Gadoversetamide Injection. HO It is usually available as solutions containing 54.84 to 76.78% of Proprietary Preparations (details are given in Part 3) iobitridol (equivalent to 250 to 350 mg/mL of iodine). The dose Arg.: Optimark; Austral.: Optimark; Canad.: Optimark; Cz.: Optimark; O and strength used varies depending on the procedure and route. Port.: Optimark; USA: Optimark. OH ◊ References. HO OH 1. Petersein J, et al. Results of the safety and efficacy of iobitridol in more than 61,000 patients. Eur Radiol 2003; 13: 2006–11. HO Gadoxetic Acid (rINN) Preparations Acide Gadoxétique; Ácido gadoxético; Acidum Gadoxeticum; Pharmacopoeias. In Eur. (see p.vii). Also in USNF. Proprietary Preparations (details are given in Part 3) Gd-EOB-DTPA. Dihydrogen [N-{(2S)-2-[bis(carboxymethyl)- Arg.: Xenetic; Xenetix; Austria: Xenetix; Belg.: Xenetix; Braz.: Henetix†; Ph. Eur. 6.2 (Galactose). A white or almost white, crystalline or Chile: Xenetix; Cz.: Xenetix; Denm.: Xenetix; Fin.: Xenetix; Fr.: Xenetix; amino]-3-(p-ethoxyphenyl)propyl}-N-{2-[bis(carboxymethyl)- finely granulated powder. Freely soluble or soluble in water; very Ger.: Xenetix; Gr.: Xenetix; Hung.: Xenetix; Israel: Xenetix; Ital.: amino]ethyl}glycinato(5−)]gadolinate(2−). slightly soluble in alcohol. Xenetix; Neth.: Xenetix; Norw.: Xenetix; Port.: Xenetix; Spain: Xenetix; Swed.: Xenetix; Switz.: Xenetix; Venez.: Xenetix. Гадоксетовая Кислота USNF 26 (Galactose). A white, crystalline or finely granulated powder. Soluble in water; very slightly soluble in alcohol. Store C23H30GdN3O11 = 681.7. in airtight containers. CAS — 135326-11-3 (gadoxetic acid).
    [Show full text]
  • Pharmacologyonline 2: 497-517 (2010) Ewsletter Bernardi Et
    Pharmacologyonline 2: 497-517 (2010) ewsletter Bernardi et al. IOIC AD OIOIC COTRAST AGETS. A COTRIBUTIO BY WHO-ITA AD THE DRUG DOCUMETATIO AD IFORMATIO CETRE OF REGIOE MARCHE (°). Marina Bernardi, Dan Bradu, Bernardino Di Sarra, Gerardo Galeazzi, Mario Marcucci, Giuditta Montecchiani, Vincenzo Moretti, Luca Moroni, Lamberto Re, Luigi Rossini, Paola Rossini, Cecilia Tonnini Istituto di Medicina Sperimentale e Clinica, Servizio di Farmacologia Clinica e Tossicologia Centro nazionale collaborativo WHO-ITA / ITA-OMS di Farmacoepidemiologia, Università degli Studi di Ancona. Summary This is the first work on ionic and nonionic contrast media on the data collected up to 1989, reconfirmed July 2010, in the WHO Data Bank of the International Drug Monitoring Programme, based at Uppsala University and funded by grants from the Swedish Crown and Government. WHO-ITA / ITA-OMS, the denomination approved by the WHO Assembly, has been authorized in 1989 to use these data as the Italian representative, through delegation by the Health Minister of Italy, the sixth founding member of the System and the first to adhere to the network for the International exchange of data on adverse reactions (ADR) and events related to ionic (5) and non-ionic (2) contrast agents employed in the then participating countries. The database is highly heterogeneous, collecting data reported spontaneously or by regulation, verified as well as non-verified, sometimes published in the international scientific literature as isolated reports. The cases of ADR and/or adverse events
    [Show full text]